ArticleFrontiers in immunology2026

Fulminant multi-organ myositis as a rare immune-related adverse event of nivolumab-relatlimab (Opdualag) therapy in metastatic melanoma: a case report.

Adi Moyal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.